Mirikizumab for Ulcerative Colitis: A Game-Changer or Just Another Incremental Advance?

Dig Dis Sci. 2025 Apr 16. doi: 10.1007/s10620-025-09047-2. Online ahead of print.

Authors

Bisher Sawaf¹, Shahem Abbarh², Dahham Alsoud³

Affiliations

¹ Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, USA.
² Department of Internal Medicine, MedStar Health, Baltimore, MD, USA.
³ Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. dahhamalsoud@gmail.com.

PMID: 40237908
DOI: 10.1007/s10620-025-09047-2

No abstract available

Keywords: Interleukins; Random clinical trials; Therapeutic monoclonal antibodies; Ulcerative colitis.

Publication types

Editorial